Alto Neuroscience, Inc.
NYSE:ANROBiotechnology
+$0.40 today
- Market cap
- $999.16M
- Beta
- 1.25
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$2.26
Volume 0.50M
Average 0.34M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Alto Neuroscience, Inc.
NYSE:ANRO
Intrinsic Alpha fair value
Locked
Current Price
$24.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Alpha Tau Medical Ltd. NASDAQ:DRTS | $1.24B | $13.38 | Not rated | -15.2 | +228.53% |
Silence Therapeutics plc NASDAQ:SLN | $936.65M | $19.83 | Not rated | -3.9 | +193.33% |
Contineum Therapeutics, Inc. Class A Common Stock NASDAQ:CTNM | $348.58M | $9.86 | Not rated | -7.5 | -17.03% |
Larimar Therapeutics, Inc. NASDAQ:LRMR | $313.73M | $3.02 | Not rated | -1.8 | -11.80% |
DBV Technologies S.A. NASDAQ:DBVT | $263.50M | $11.02 | Not rated | -8.3 | -28.28% |
Amarin Corporation plc NASDAQ:AMRN | $235.37M | $11.38 | Not rated | -9.9 | -32.56% |
AC Immune S.A. NASDAQ:ACIU | $216.78M | $2.13 | Not rated | -2.9 | -30.82% |
Korro Bio, Inc. NASDAQ:KRRO | $196.29M | $13.61 | Not rated | -1.3 | +98.07% |
Cellectis S.A. NASDAQ:CLLS | $118.86M | $1.18 | Not rated | -4.6 | -74.21% |
Aldeyra Therapeutics, Inc. NASDAQ:ALDX | $38.86M | $0.64 | Not rated | -4.2 | -81.67% |
Continue the stock analysis
Jump to another research area for this company.